Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2643096
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Combination therapy with trastuzumab and pertuzumab 1) Trastuzumab: 8 mg/kg (first dose), 6 mg/kg (second and subsequent doses), every 3 weeks 2) Pertuzumab: 840 mg (first dose), 420 mg (second and subsequent doses), every 3 weeks Both drugs will be intravenously administered.
Primary outcome(s): Confirmed objective response rate (ORR) by investigators’ assessment
Study Design: Single arm Non-randomized
创建时间：
2017-12-15
